You are now leaving the Lilly Medical website
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Rezvoglar ™ (insulin glargine-aglr) injection
3 mL (100 units/mL)
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Is Rezvoglar™ (insulin glargine-aglr) biosimilar to, and interchangeable with, Semglee® (insulin glargine‑yfgn)?
Rezvoglar is not biosimilar to, or interchangeable with, Semglee.
Rezvoglar and Interchangeability With Semglee
Rezvoglar™ (insulin glargine-aglr) 100 units/mL is not approved as biosimilar to, or interchangeable with, Semglee® (insulin glargine-yfgn) 100 units/mL.1
Pharmacists cannot substitute Rezvoglar for Semglee without a new prescription. Health care professionals will need to write a new prescription for Rezvoglar.
Rezvoglar™ (insulin glargine-aglr) 100 units/mL is biosimilar to Lantus® (insulin glargine).1
Enclosed Prescribing Information
Reference
1Rezvoglar [package insert]. Indianapolis, IN: Eli Lilly and Company; 2024.
Date of Last Review: March 09, 2026